Bio-Techne Introduces Innovative ESR1 Mutation Assay
Bio-Techne Corporation (NASDAQ: TECH) is leading the way in breast cancer research with the launch of their latest assay designed to monitor ESR1 mutations. This assay will be showcased at a prominent upcoming symposium focused on breast cancer advancements. The new tool aims to assist in identifying mutations critical for patients undergoing treatment for hormone receptor-positive metastatic breast cancer.
Understanding the Importance of ESR1 Mutations
ESR1 gene mutations play a pivotal role in the treatment landscape of metastatic breast cancer. Studies suggest that while these mutations are rare prior to treatment, their occurrence increases significantly with endocrine therapies, affecting up to 40% of patients. Early detection of these mutations is essential for healthcare providers to swiftly adapt treatment plans and combat rising resistance. Traditional testing methods often fall short in sensitivity, making the introduction of this assay a significant advancement in cancer care.
Details of the New Assay
The ESR1 mutation monitoring assay employs a combination of a qPCR detection kit and a sophisticated isolation kit for both cell-free DNA and exosomal RNA. This dual approach enhances the ability to detect a comprehensive range of 11 ESR1 mutations with remarkable precision. It stands out because it utilizes readily available qPCR technology, negating the need for expensive investments in new testing platforms, making it accessible for many laboratories.
Expert Insights from Bio-Techne
Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, highlighted the assay's significance considering the growing focus on targeted drugs for ESR1 mutations. His insights emphasize the need for scientists to be equipped with tools that can easily identify these mutations, particularly for patients who may have already been treated with aromatase inhibitors. Bio-Techne’s commitment to creating high-quality, practical solutions is solidified by this innovative assay.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a premier life sciences entity dedicated to providing advanced tools and bioactive reagents aimed at the research and clinical diagnostic realms. With a rich portfolio that includes hundreds of thousands of products, Bio-Techne generates substantial revenue and employs around 3,100 individuals globally. Their efforts contribute significantly to enhancing scientific research as well as improving clinical diagnostic accuracy.
For more insights on Bio-Techne and its innovations, interested parties can follow their various social media platforms for updates and information about new product developments.
Frequently Asked Questions
What is the significance of the ESR1 mutation assay?
The assay is designed to detect ESR1 mutations that can indicate treatment resistance in patients with metastatic breast cancer, enabling swift clinical responses.
How does the new assay differ from existing tests?
This assay offers higher sensitivity and the ability to detect multiple mutations using familiar qPCR technology, making it more efficient and cost-effective.
What impact do ESR1 mutations have on treatment options?
Identifying these mutations helps clinicians choose the most effective treatments, especially as new targeted therapies become available.
Is the ESR1 mutation assay available for diagnostic use?
Currently, the Assay is intended solely for research use and is not approved for diagnostic purposes.
What is Bio-Techne's role in the life sciences sector?
Bio-Techne develops innovative tools and reagents that support research and clinical diagnostics, contributing to advancements in understanding diseases and supporting drug discovery.
